参考文献/References:
[1]Robinson SC,Brucer M. Range of normal blood pressure:a statistical and clinical study of 11,383 persons[J]. Arch Intern Med,1939,64(3):409-444.
[2]Chobanian AV,Bakris GL,Black HR,et al. The Seventh Report of the Joint National Committee on Prevention,Detection,Evaluation,and Treatment of High Blood Pressure:the JNC 7 report[J]. JAMA,2003,289(19):2560-2572.
[3]Joint Committee for Guideline Revision. 2018 Chinese Guidelines for Prevention and Treatment of Hypertension—a report of the revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension[J]. J Geriatr Cardiol,2019,16(3):182-241.
[4]Wang Y,Wang QJ. The prevalence of prehypertension and hypertension among US adults according to the new joint national committee guidelines:new challenges of the old problem[J]. Arch Intern Med,2004,164(19):2126-2134.
[5]Xu T,Liu J,Zhu G,et al. Prevalence of prehypertension and associated risk factors among Chinese adults from a large-scale multi-ethnic population survey[J]. BMC Public Health,2016,16(1):775.
[6]Chen CY,Yuan ZP. Prevalence and risk factors for prehypertension and hypertension among adults in Central China from 2000-2011[J]. Clin Exp Hypertens,2018,40(8):734-743.
[7]Selassie A,Wagner CS,Laken ML,et al. Progression is accelerated from prehypertension to hypertension in blacks[J]. Hypertension,2011,58(4):579-587.
[8]Vasan RS,Larson MG,Leip EP,et al. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study:a cohort study[J]. Lancet,2001,358(9294):1682-1686.
[9]Faselis C,Doumas M,Kokkinos JP,et al. Exercise capacity and progression from prehypertension to hypertension[J]. Hypertension,2012,60(2):333-338.
[10] Guo X,Zhang X,Guo L,et al. Association between pre-hypertension and cardiovascular outcomes:a systematic review and meta-analysis of prospective studies[J]. Curr Hypertens Rep,2013,15(6):703-716.
[11] Han M,Li Q,Liu L,et al. Prehypertension and risk of cardiovascular diseases:a meta-analysis of 47 cohort studies[J]. J Hypertens,2019,37(12):2325-2332.
[12] Lewington S,Clarke R,Qizilbash N,et al. Age-specific relevance of usual blood pressure to vascular mortality:a meta-analysis of individual data for one million adults in 61 prospective studies[J]. Lancet,2002,360(9349):1903-1913.
[13] Huang Y,Cai X,Zhang J,et al. Prehypertension and Incidence of ESRD:a systematic review and meta-analysis[J]. Am J Kidney Dis,2014,63(1):76-83.
[14] Huang Y,Cai X,Li Y,et al. Prehypertension and the risk of stroke:a meta-analysis[J]. Neurology,2014,82(13):1153-1161.
[15] Stoll G,Bendszus M. Inflammation and atherosclerosis:novel insights into plaque formation and destabilization[J]. Stroke,2006,37(7):1923-1932.
[16] Dinh QN,Drummond GR,Sobey CG,et al. Roles of inflammation,oxidative stress,and vascular dysfunction in hypertension[J]. Biomed Res Int,2014,2014:406960.
[17] Verma S,Wang CH,Li SH,et al. A self-fulfilling prophecy:C-reactive protein attenuates nitric oxide production and inhibits angiogenesis[J]. Circulation,2002,106(8):913-919.
[18] Fichtlscherer S,Rosenberger G,Walter DH,et al. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease[J]. Circulation,2000,102(9):1000-1006.
[19] Chrysohoou C,Pitsavos C,Panagiotakos DB,et al. Association between prehypertension status and inflammatory markers related to atherosclerotic disease:the ATTICA Study[J]. Am J Hypertens,2004,17(7):568-573.
[20] Pitsavos C,Chrysohoou C,Panagiotakos DB,et al. Abdominal obesity and inflammation predicts hypertension among prehypertensive men and women:the ATTICA Study[J]. Heart Vessels,2008,23(2):96-103.
[21] Zhang S,Xu T,Peng Y,et al. Combined action of C-reactive protein and lipid profiles on risk of hypertension and prehypertension in Mongolian adults in Inner Mongolia, China[J]. Chin Med J (Engl),2014,127(11):2016-2020.
[22] Jinghua L,Tie Z,Ping W,et al. The relationship between serum sialic acid and high-sensitivity C-reactive protein with prehypertension[J]. Med Sci Monit,2014,20:551-555.
[23] 富玮辰,王瑞英.血清尿酸和超敏C-反应蛋白在高血压前期的变化及临床意义[J].中西医结合心脑血管病杂志,2019,17(6):908-910.
[24] Mozos I,Jianu D,Gug C,et al. Links between high-sensitivity C-reactive protein and pulse wave analysis in middle-aged patients with hypertension and high normal blood pressure[J]. Dis Markers,2019,2019:2568069.
[25] Pan L,Li G,Wan S,et al. The association between high-sensitivity C-reactive protein and blood pressure in Yi people[J]. BMC Public Health,2019,19(1):991.
[26] Sesso HD,Buring JE,Rifai N,et al. C-reactive protein and the risk of developing hypertension[J]. JAMA,2003,290(22):2945-2951.
[27] Yao W,Sun Y,Wang X,et al. Elevated serum level of interleukin 17 in a population with prehypertension[J]. J Clin Hypertens (Greenwich),2015,17(10):770-774.
[28] Langenberg C,Bergstrom J,Scheidt-Nave C,et al. Cardiovascular death and the metabolic syndrome:role of adiposity-signaling hormones and inflammatory markers[J]. Diabetes Care,2006,29(6):1363-1369.
[29] Fung MM,Rao F,Poddar S,et al. Early inflammatory and metabolic changes in association with AGTR1 polymorphisms in prehypertensive subjects[J]. Am J Hypertens,2011,24(2):225-233.
[30] 王变丽,任军梅,药华,等.高血压前期人群血管炎性因子的临床分析[J].长治医学院学报,2017,31(2):115-117.
[31] Tseke P,Grapsa E,Stamatelopoulos K,et al. Correlations of sialic acid with markers of i nflammation,atherosclerosis and cardiovascular events in hemodialysis patients[J]. Blood Purif,2008,26(3):261-266.
[32] 柏居林,王伟.血清唾液酸、超敏C反应蛋白与高血压前期的关系及临床意义[J].临床医学研究与实践,2018,3(27):111-112.
[33] Talikoti P, Bobby Z,Hamide A. Hyperhomocysteinemia,insulin resistance and high hs-CRP levels in prehypertension[J]. J Clin Diagn Res,2014,8(8):CC07-CC09.
[34] 侯惠丽,陈瑛,吴萍,等.同型半胱氨酸水平对高血压前期患者进展为高血压的预测价值研究[J].中国全科医学,2018,21(22):2702-2706.
[35] Liu B,Chen Z,Dong X,et al. Association of prehypertension and hyperhomocysteinemia with subclinical atherosclerosis in asymptomatic Chinese:a cross-sectional study[J]. BMJ Open,2018,8(3):e019829.
[36] Shields KJ,Stolz D,Watkins SC,et al. Complement proteins C3 and C4 bind to collagen and elastin in the vascular wall:a potential role in vascular stiffness and atherosclerosis[J]. Clin Transl Sci,2011,4(3):146-152.
[37] Han Y,Fukuda N,Ueno T,et al. Role of complement 3a in the synthetic phenotype and angiotensinⅡ-production in vascular smooth muscle cells from spontaneously hypertensive rats[J]. Am J Hypertens,2012,25(3):284-289.
[38] Bao X,Meng G,Zhang Q,et al. Elevated serum complement C3 levels are associated with prehypertension in an adult population[J]. Clin Exp Hypertens,2017,39(1):42-49.
相似文献/References:
[1]孙静美 尹德春 曲秀芬.炎症信号与心房颤动[J].心血管病学进展,2020,(1):31.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.009]
SUN Jingmei,YIN Dechun,QU Xiufen.Inflammatory Signals Associated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2020,(11):31.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.009]
[2]朱晓龙侯阳.细胞焦亡的分子机制其在心血管病变中的研究进展[J].心血管病学进展,2020,(8):847.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.016]
ZHU Xiaolong,HOU Yang.Molecular Mechanism of yroptosis and Its Research Progress in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2020,(11):847.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.016]
[3]张菲菲 周子皓 王芳.白介素在血管钙化作用机制中的研究进展[J].心血管病学进展,2021,(4):364.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.018]
HANG Feifei,ZHOU Zihao,WANG Fang?/html>.Research Progress of Interleukin in the Mechanism?f Vascular Calcification[J].Advances in Cardiovascular Diseases,2021,(11):364.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.018]
[4]魏天天?王学超?吴海波?杜荣品.心力衰竭生物标志物的研究进展[J].心血管病学进展,2021,(7):610.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.009]
WEI Tiantian,WANG Xuechao,WU Haibo,et al.Biomarkers of Heart Failure[J].Advances in Cardiovascular Diseases,2021,(11):610.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.009]
[5]王兰 叶玉兰 宁明安 张迪 尚粉青.血清PCSK9水平与PCI后冠状动脉病变再进展的关系研究[J].心血管病学进展,2022,(7):667.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
WANG Lan,YE Yulan,NING Mingan,et al.Correlation Analysis Between Serum PCSK9 Level and Coronary Artery Pathological ?Progression After PCI[J].Advances in Cardiovascular Diseases,2022,(11):667.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
[6]刘星宇 张颖.正常高值血压人群：血压变异性和心室重塑的研究进展[J].心血管病学进展,2023,(2):150.[doi:10.16806/j.cnki.issn.1004-3934.2023.02.012]
LIU XingyuZhang Ying.People with High-Normal Blood Pressure:Blood Pressure Variability and Ventricular Remodeling[J].Advances in Cardiovascular Diseases,2023,(11):150.[doi:10.16806/j.cnki.issn.1004-3934.2023.02.012]
[7]王朝阳 赵丽娜 田师鹏 陈淑霞 谷剑.炎症治疗在动脉粥样硬化中的研究进展[J].心血管病学进展,2023,(6):519.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.009]
WANG Zhaoyang,ZHAO Lina,TIAN Shipeng,et al.Advances in the Treatment of Inflammation in Atherosclerosis[J].Advances in Cardiovascular Diseases,2023,(11):519.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.009]
[8]张晓婷 郭衍楷 汤宝鹏.心房颤动与白介素家族的研究进展[J].心血管病学进展,2024,(4):340.[doi:10.16806/j.cnki.issn.1004-3934.2024.04.012]
ZHANG Xiaoting,GUO Yankai,TANG Baopeng.Interleukin Family and Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2024,(11):340.[doi:10.16806/j.cnki.issn.1004-3934.2024.04.012]